{"entity":{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","aka":["ILT2","LIR-1","CD85j","leukocyte immunoglobulin like receptor B1"],"tldr":"LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.","summary":"LILRB1 (chromosome 19q13.42) is a receptor for class I MHC antigens that recognises a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles and the cytomegalovirus homologue UL18; ligand binding gives inhibitory signals and down-regulates the immune response, and engagement on NK or T cells protects the target from lysis. It is expressed in B cells, monocytes and myeloid, plasmacytoid and tolerogenic dendritic cells, in decidual macrophages and decidual NK cells (protein level) (UniProt Q8NHL6). NGM707, an antibody against LILRB1 and LILRB2, was studied in phase 1/2 with pembrolizumab (NCT04913337); a later phase 2 study was withdrawn by the sponsor (NCT07511972).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:6605","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6605"},{"label":"UniProt Q8NHL6","url":"https://www.uniprot.org/uniprotkb/Q8NHL6/entry"},{"label":"NCBI Gene 10859","url":"https://www.ncbi.nlm.nih.gov/gene/10859"},{"label":"ClinicalTrials.gov NCT04913337","url":"https://clinicaltrials.gov/study/NCT04913337"}],"tags":["checkpoint-map"],"related":["lilrb2","hla-a","pembrolizumab"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"LILRB1","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:6605","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6605","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt Q8NHL6","url":"https://www.uniprot.org/uniprotkb/Q8NHL6/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:6605","ensembl":"ENSG00000104972","uniprot":"Q8NHL6","entrez":"10859","biology":"An ITIM-bearing LILR; LILRB receptors negatively regulate myeloid maturation and permit a suppressive myeloid phenotype in tumours (van der Touw et al. 2017).","whereFound":["B cells, monocytes, dendritic cells, decidual macrophages and NK cells (UniProt Q8NHL6)"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/lilrb1/","neighbours":{"target":[{"id":"hla-a","kind":"target","name":"HLA-A","route":"/targets/hla-a/"},{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}